{
 "name": "竟天",
 "slug": "tw-6917",
 "aliases": [
  "竟天生物科技股份有限公司",
  "Andros",
  "6917"
 ],
 "ticker": "6917",
 "industry": "生技醫療業",
 "website": "http://www.androspharma.com",
 "summary": "竟天（6917）是興櫃的生技醫療類股公司，2008 年成立，2023 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "竟天生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "Andros",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2023-01-12",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2008-07-21",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "王藹君",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "王藹君",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 552720000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "http://www.androspharma.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：APC101（lidocaine 5% spray）",
   "value": "帶狀疱疹後神經痛｜第二期b／第三期臨床試驗已登錄，尚未招募｜美國、澳洲",
   "unit": "",
   "as_of": "2026-05-20",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07599800",
   "note": "NCT07599800；Last Update Posted 2026-05-20；PHASE2/PHASE3、NOT_YET_RECRUITING。2026-03-04公司法說第13頁另確認美澳IND；登錄預估2026-08-01開始但未更新為實際開始，不宣稱已收案。"
  },
  {
   "claim": "管線：APC101（lidocaine 5% spray；頭頸部適應症）",
   "value": "頭頸部帶狀疱疹後神經痛｜第二期臨床試驗｜台灣",
   "unit": "",
   "as_of": "2026-03-04",
   "source": "https://mopsov.twse.com.tw/nas/STR/691720260304M001.pdf",
   "note": "法說簡報第13頁分列台灣頭頸部Phase II，與美澳全身性Phase IIb/III不同試驗。"
  },
  {
   "claim": "管線：APC201（diclofenac 4% foam）",
   "value": "膝骨關節炎局部疼痛｜第一期／第二期a已完成，2025-11臨床試驗報告完稿｜澳洲",
   "unit": "",
   "as_of": "2026-03-04",
   "source": "https://mopsov.twse.com.tw/nas/STR/691720260304M001.pdf",
   "note": "法說簡報第18頁明載Phase IIa完成及2025-11 CSR完稿；後續美澳歐IND為原訂2026-Q2計畫，未據此宣稱已核准。"
  },
  {
   "claim": "授權合作：酒糟性皮膚炎外用學名藥（代號未揭露）",
   "value": "永信藥品工業股份有限公司｜台灣（初期目標市場）｜2025-08-07",
   "unit": "",
   "as_of": "2025-08-07",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢6917、114年度、全年度、序號2。發言日期2025-08-07 15:55:40；主旨：本公司與永信藥品工業股份有限公司簽訂合作開發暨授權合約。竟天負責開發、生產；永信負責法規、藥證及上市後行銷銷售。公告未公開成分、代號、簽約金額、里程碑金額或分潤比例，不自行對應APC601。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-6917.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}